Older melanoma patients have better response to immune checkpoint blockade therapy

(The Wistar Institute) Patient age correlates with response to immunotherapy in melanoma and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The Wistar Institute.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news